Mesoblast Stock Earnings Reports

Mesoblast reported a successful transition to commercialization in FY2025 after FDA approval and launch of Ryoncil (remestemcel-L), the first and only FDA‑approved mesenchymal stromal cell (MSC) therapy in the U.S. Key financials: product revenue from cell therapies was $17.2M (up 191% YoY), driven by $13.2M gross sales of Ryoncil in the launch quarter and $11.3M net sales after a 14.6% gross‑to‑net adjustment; gross margin on product sales was ~90%; net operating cash spend was ~$50M and cash on hand stood at $162M (USD). Commercial progress: 32 transplant centers onboarded to date with a goal of top 45 centers (covering ~80% of pediatric bone marrow transplants) by end of the current quarter; payer coverage now represents over 250M covered lives with Medicaid coverage in all states effective July 1; a specific J‑code for Ryoncil is effective Oct 1. Clinical and pipeline updates: pivotal data underpinning pediatric acute steroid‑refractory GvHD showed a 70% day‑28 response and durable long‑term survival; Mesoblast plans a pivotal adult severe acute GvHD trial (adding Ryoncil on top of ruxolitinib) to start this quarter with the NIH BMT‑CTN; plans to initiate a pivotal program in medically‑refractory inflammatory colitis (IBD) using local and/or IV delivery; rexlemestrocel‑L (second‑generation MSC) is in Phase III for chronic low back pain (confirmatory trial actively enrolling, targeting last‑patient‑in end of this year/early next year) and Mesoblast is preparing for an accelerated approval filing for Revascor in chronic heart failure following FDA alignment on CMC, potency and confirmatory trial design. Risks/notes: warrant and contingent consideration non‑cash revaluation losses impacted FY25 results; guidance on near‑term revenue trajectory was not provided beyond noting continued strengthening as the launch matures.